m6A甲基转移酶METTL3通过抑制RIG-I-MAVS天然免疫途径促进非小细胞肺癌进展。

m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway.

作者信息

Huang Tinghui, Ao Xudong, Liu Jie, Sun Chuancheng, Dong Yunfei, Yin Xuechen, Zhang Yan, Wang Xinping, Li Wenying, Cao Jiujiu, Pan Feiyan, Hu Zhigang, Guo Zhigang, He Lingfeng

机构信息

Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 WenYuan Road, Nanjing 210023, China.

Peking University Cancer Hospital (Inner Mongolia Campus)/Affiliated Cancer Hospital of Inner Mongolia Medical University. No. 42, Zhaowuda Road, Saihan District, Hohhot, Inner Mongolia Autonomous Region, 010000, China.

出版信息

Transl Oncol. 2025 Jan;51:102230. doi: 10.1016/j.tranon.2024.102230. Epub 2024 Dec 2.

Our experimental study showed that METTL3 was highly expressed in NSCLC cells and promoted the growth of tumor cells. METTL3 takes N6-methyladenosine (m6A) as the main means of mRNA modification to control the expression and function of RIG-I-MAVS signalling pathway. RIG-I-MAVS constitute the first line frontier in the innate immune defense of human cells. Activation of RIG-I-MAVS signaling can inhibit tumor cell growth and activate the immune microenvironment. Our experimental data reveal that lung cancer cells utilize METTL3-mediated methylation modifications to inhibit the activation of RIG-I-MAVS signaling pathway and immune responses. Our work provides new ideas for biotherapy and immunotherapy.